Literature DB >> 10899625

Angiotensin II generation by mast cell alpha- and beta-chymases.

G H Caughey1, W W Raymond, P J Wolters.   

Abstract

Mast cells secrete alpha- and beta-chymases. Primate alpha-chymases generate angiotensin (AT) II by selectively hydrolyzing AT I's Phe(8)-His(9) bond. This is distinct from the AT converting enzyme (ACE) pathway. In humans, alpha-chymase is the major non-ACE AT II-generator. In rats, beta-chymases destroy AT II by cleaving at Tyr(4)-Ile(5). Past studies predicted that AT II production versus destruction discriminates alpha- from beta-chymases and that Lys(40) in the substrate-binding pocket determines alpha-chymase Phe(8) specificity. This study examines these hypotheses by comparing AT II generation by human alpha-chymase (containing Lys(40)), dog alpha-chymase (lacking Lys(40)), and mouse mMCP-4 (a beta-chymase lacking Lys(40); orthologous to AT II-destroying rat chymase rMCP-1). The results suggest that human and dog alpha-chymase generate AT II exclusively and with comparable efficiency, although dog chymase contains Ala(40) rather than Lys(40). Furthermore, AT II is the major product generated by degranulation supernatants from cultured dog mast cells, which release tryptases and dipeptidylpeptidase as well as alpha-chymase. In contrast to rMCP-1, mMCP-4 beta-chymase readily generates AT II. Although there is competing AT I hydrolysis at Tyr(4), mMCP-4 does not destroy AT II quickly once it is formed. We conclude (1) that chymases are the dominant AT I-hydrolyzing mast cell peptidases, (2) that residues other than Lys(40) are key determinants of alpha-chymase AT I Phe(8) specificity, (3) that beta-chymases can generate AT II, and (4) that alpha- and beta-chymases are not strictly dichotomous regarding AT I cleavage specificity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899625     DOI: 10.1016/s0167-4838(00)00076-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  63 in total

1.  Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis.

Authors:  Lisa Scandiuzzi; Walid Beghdadi; Eric Daugas; Magnus Abrink; Neeraj Tiwari; Cristiana Brochetta; Julien Claver; Nassim Arouche; Xingxing Zang; Marina Pretolani; Renato C Monteiro; Gunnar Pejler; Ulrich Blank
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 2.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

Review 3.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

4.  The inflammatory response after an epidermal burn depends on the activities of mouse mast cell proteases 4 and 5.

Authors:  George Younan; Freeman Suber; Wei Xing; Tong Shi; Yuichi Kunori; Magnus Abrink; Gunnar Pejler; Susan M Schlenner; Hans-Reimer Rodewald; Francis D Moore; Richard L Stevens; Roberto Adachi; K Frank Austen; Michael F Gurish
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

5.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 6.  Mast cell tryptases and chymases in inflammation and host defense.

Authors:  George H Caughey
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

7.  Possible roles of mast cell-derived chymase for skin rejuvenation.

Authors:  Nobuyuki Amano; Shinji Takai; Denan Jin; Koichi Ueda; Mizuo Miyazaki
Journal:  Lasers Med Sci       Date:  2008-04-12       Impact factor: 3.161

Review 8.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

Review 9.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

Review 10.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.